Weight Loss Drug Mounjaro to Launch in India, Know All About It

Eli Lilly’s weight loss drug Mounjaro (tirzepatide) has recently launched in India, offering a new treatment option for adults with obesity and type 2 diabetes. Mounjaro works by targeting GLP-1 and GIP receptors, which helps regulate blood sugar and reduce appetite through slower gastric emptying. Administered as a weekly injection, it has shown promising results in clinical trials. Priced more affordably in India compared to the U.S., Mounjaro has already sparked high demand among patients and doctors. Common side effects include nausea, vomiting, and diarrhea, so medical supervision is essential. This launch marks a significant step in addressing obesity in India.

Read More